Literature DB >> 28057736

Acute myeloid leukemias with ring sideroblasts show a unique molecular signature straddling secondary acute myeloid leukemia and de novo acute myeloid leukemia.

Pedro Martin-Cabrera1, Sabine Jeromin1, Karolína Perglerovà2, Claudia Haferlach1, Wolfgang Kern1, Torsten Haferlach3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28057736      PMCID： PMC5395122          DOI： 10.3324/haematol.2016.156844

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  13 in total

1.  Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations.

Authors:  Sabine Jeromin; Torsten Haferlach; Sandra Weissmann; Manja Meggendorfer; Christiane Eder; Niroshan Nadarajah; Tamara Alpermann; Alexander Kohlmann; Wolfgang Kern; Claudia Haferlach; Susanne Schnittger
Journal:  Haematologica       Date:  2014-12-19       Impact factor: 9.941

2.  Risk assessment by monitoring expression levels of partial tandem duplications in the MLL gene in acute myeloid leukemia during therapy.

Authors:  Martin Weisser; Wolfgang Kern; Claudia Schoch; Wolfgang Hiddemann; Torsten Haferlach; Susanne Schnittger
Journal:  Haematologica       Date:  2005-07       Impact factor: 9.941

3.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

Authors:  David Grimwade; Robert K Hills; Anthony V Moorman; Helen Walker; Stephen Chatters; Anthony H Goldstone; Keith Wheatley; Christine J Harrison; Alan K Burnett
Journal:  Blood       Date:  2010-04-12       Impact factor: 22.113

4.  Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis.

Authors:  Christian Thiede; Christine Steudel; Brigitte Mohr; Markus Schaich; Ulrike Schäkel; Uwe Platzbecker; Martin Wermke; Martin Bornhäuser; Markus Ritter; Andreas Neubauer; Gerhard Ehninger; Thomas Illmer
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

5.  Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.

Authors:  R Coleman Lindsley; Brenton G Mar; Emanuele Mazzola; Peter V Grauman; Sarah Shareef; Steven L Allen; Arnaud Pigneux; Meir Wetzler; Robert K Stuart; Harry P Erba; Lloyd E Damon; Bayard L Powell; Neal Lindeman; David P Steensma; Martha Wadleigh; Daniel J DeAngelo; Donna Neuberg; Richard M Stone; Benjamin L Ebert
Journal:  Blood       Date:  2014-12-30       Impact factor: 22.113

6.  Frequent pathway mutations of splicing machinery in myelodysplasia.

Authors:  Kenichi Yoshida; Masashi Sanada; Yuichi Shiraishi; Daniel Nowak; Yasunobu Nagata; Ryo Yamamoto; Yusuke Sato; Aiko Sato-Otsubo; Ayana Kon; Masao Nagasaki; George Chalkidis; Yutaka Suzuki; Masashi Shiosaka; Ryoichiro Kawahata; Tomoyuki Yamaguchi; Makoto Otsu; Naoshi Obara; Mamiko Sakata-Yanagimoto; Ken Ishiyama; Hiraku Mori; Florian Nolte; Wolf-Karsten Hofmann; Shuichi Miyawaki; Sumio Sugano; Claudia Haferlach; H Phillip Koeffler; Lee-Yung Shih; Torsten Haferlach; Shigeru Chiba; Hiromitsu Nakauchi; Satoru Miyano; Seishi Ogawa
Journal:  Nature       Date:  2011-09-11       Impact factor: 49.962

7.  SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value.

Authors:  Mrinal M Patnaik; Terra L Lasho; Janice M Hodnefield; Ryan A Knudson; Rhett P Ketterling; Guillermo Garcia-Manero; David P Steensma; Animesh Pardanani; Curtis A Hanson; Ayalew Tefferi
Journal:  Blood       Date:  2011-11-17       Impact factor: 22.113

Review 8.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

9.  Prevalence and distribution of ringed sideroblasts in primary myelodysplastic syndromes.

Authors:  S K Juneja; M Imbert; F Sigaux; H Jouault; C Sultan
Journal:  J Clin Pathol       Date:  1983-05       Impact factor: 3.411

10.  Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.

Authors:  E Papaemmanuil; M Cazzola; J Boultwood; L Malcovati; P Vyas; D Bowen; A Pellagatti; J S Wainscoat; E Hellstrom-Lindberg; C Gambacorti-Passerini; A L Godfrey; I Rapado; A Cvejic; R Rance; C McGee; P Ellis; L J Mudie; P J Stephens; S McLaren; C E Massie; P S Tarpey; I Varela; S Nik-Zainal; H R Davies; A Shlien; D Jones; K Raine; J Hinton; A P Butler; J W Teague; E J Baxter; J Score; A Galli; M G Della Porta; E Travaglino; M Groves; S Tauro; N C Munshi; K C Anderson; A El-Naggar; A Fischer; V Mustonen; A J Warren; N C P Cross; A R Green; P A Futreal; M R Stratton; P J Campbell
Journal:  N Engl J Med       Date:  2011-09-26       Impact factor: 91.245
View more
  3 in total

1.  Ring sideroblasts in AML are associated with adverse risk characteristics and have a distinct gene expression pattern.

Authors:  Gerbrig Berger; Mylene Gerritsen; Guoqiang Yi; Theresia N Koorenhof-Scheele; Leonie I Kroeze; Marian Stevens-Kroef; Kenichi Yoshida; Yuichi Shiraishi; Eva van den Berg; Hein Schepers; Geert Huls; André B Mulder; Seishi Ogawa; Joost H A Martens; Joop H Jansen; Edo Vellenga
Journal:  Blood Adv       Date:  2019-10-22

Review 2.  Causes and Pathophysiology of Acquired Sideroblastic Anemia.

Authors:  Juan Jose Rodriguez-Sevilla; Xavier Calvo; Leonor Arenillas
Journal:  Genes (Basel)       Date:  2022-08-30       Impact factor: 4.141

3.  Acquired Sideroblastic Anemia: An Exploratory Comparative Statistical Analysis Between Clonal and Non-clonal Cases.

Authors:  Dina S Soliman; Samah Kohla; Shehab Fareed; Susanna Akiki; Aliaa Amer; Ibrahim Ganwo; Prem Chandra; Halima El-Omri; Feryal Ibrahim
Journal:  Mediterr J Hematol Infect Dis       Date:  2022-09-01       Impact factor: 3.122
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.